Skip to main content
CADL
NASDAQ Life Sciences

Candel Therapeutics Targets Q4 2026 BLA for Prostate Cancer Drug, Initiates Pivotal NSCLC Phase 3, Secures Funding

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$5.2
Mkt Cap
$373.559M
52W Low
$4.25
52W High
$9.08
52W Position info
22% above low
Off High info
43% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

CADL sits 22% above its 52-week low of $4.25.

Summary

Candel Therapeutics announced its fourth quarter and full year 2025 financial results alongside significant corporate highlights. The company is advancing its lead candidate, aglatimagene, towards a planned BLA submission for prostate cancer in Q4 2026 and is preparing to initiate a pivotal Phase 3 clinical trial in non-small cell lung cancer (NSCLC) in Q2 2026. Additionally, Candel received FDA clearance for its linoserpaturev IND in recurrent high-grade glioma. These clinical milestones are supported by recent strategic financing, including a term loan, a follow-on equity offering, and a royalty financing agreement, which significantly strengthens the company's balance sheet. This comprehensive update provides a clear and aggressive clinical development roadmap with multiple material catalysts throughout 2026, substantially de-risking the company's operational runway and future prospects. Investors should monitor the upcoming Q2 2026 Phase 3 prostate cancer data and the initiation of the NSCLC pivotal trial.

At the time of this announcement, CADL was trading at $5.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $373.6M. The 52-week trading range was $4.25 to $9.08. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

CADL - Latest Insights

CADL
Nov 13, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $5.11
Real-time Price: $6.10 info
Change: +$0.9897 (+19%) info
Market Cap: $486.365M info
CADL
Nov 12, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $8.39
Real-time Price: $6.10 info
Change: -$2.29 (-27%) info
Market Cap: $486.365M info
CADL
Nov 12, 2026, 4:05 PM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $8.39
Real-time Price: $6.10 info
Change: -$2.29 (-27%) info
Market Cap: $486.365M info
CADL
Oct 01, 2026, 8:05 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $10.40
Real-time Price: $6.10 info
Change: -$4.30 (-41%) info
Market Cap: $486.365M info
CADL
Sep 30, 2026, 8:05 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $10.96
Real-time Price: $6.10 info
Change: -$4.86 (-44%) info
Market Cap: $486.365M info